Wedbush analyst Liana Moussatos maintained a Buy rating on Intercept Pharma (NASDAQ:ICPT) on Friday, setting a price target of $140, which is approximately 169.96% above the present share price of $51.86.
Moussatos expects Intercept Pharma to post earnings per share (EPS) of -$2.86 for the third quarter of 2020.
The current consensus among 23 TipRanks analysts is for a Moderate Buy rating of shares in Intercept Pharma, with an average price target of $67.76.
The analysts price targets range from a high of $140 to a low of $46.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $72.65 million and a net profit of -$83.45 million. The company's market cap is $1.64 billion.
According to TipRanks.com, Wedbush analyst Liana Moussatos is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.5% and a 48.99% success rate.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.